insulin degludec vs Insulin glargine (Toujeo)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline

insulin degludec · Tresiba

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
Partial signal

NCT00982644 · Phase 3 · completed

The trial was randomized and actively controlled, with 1,030 participants, but it was not blinded and its primary endpoint was the surrogate measure of change in HbA1c rather than a hard clinical outcome. HbA1c changed by -1.06% with insulin degludec versus -1.19% with insulin glargine, but no statistical comparison is reported, so whether the primary endpoint was met is unclear.

Next expected readout: June 2027 · NCT07173712 (registry estimate)

Reported efficacy

Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52); Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes (Week 0 to Week 104 + 7 days follow up); Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes (Week 0 to Week 104 + 7 days follow up); Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs) (Week 0 to Week 104 + 7 days of follow up): Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52): IDeg OD -1.06 percentage of glycosylated haemoglobin (Standard Deviation 1.01) vs IGlar OD -1.19 percentage of glycosylated haemoglobin (Standard Deviation 0.97) (unclear)

Result source: NCT00982644

Insulin glargine (Toujeo)

Marketed by Sanofi

Approved in Type 2 Diabetespeptide
Partial signal

NCT01499082 · Phase 3 · completed

The trial was large and randomized, with an active insulin glargine comparator, and its primary HbA1c endpoint was a hard clinical treatment measure that met the prespecified non-inferiority margin. However, treatment was open-label rather than double-blinded, so the evidence is considered moderate despite the favorable non-inferiority result.

Reported efficacy

Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): HOE901-U300 -0.83 percentage of hemoglobin (Standard Error 0.06) | Lantus -0.83 percentage of hemoglobin (Standard Error 0.061) (met)

Result source: NCT01499082

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointinsulin degludecInsulin glargine (Toujeo)
HbA1c, change-1.1% vs -1.2%vs IGlaronce daily · wk 52 · n 773NCT00982644
22 other results
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · primary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 271 · Phase 3 · primary NCT02607306
  • -1.4% vs -1.6% wk 26 · n 294 · Phase 3 · primary NCT04795531
  • -1.7% vs -1.2% wk 26 · n 341 · Phase 3 · primary NCT03172494
  • -1.2% vs -1.2% wk 26 · n 167 · Phase 3 · primary NCT03172494
  • -1.9% vs -1.1% wk 26 · n 289 · Phase 3 · primary NCT03175120
  • -1.5% vs -1.4% BID · wk 26 · n 359 · Phase 3 · primary NCT02762578
  • -0.1% vs -0.1% wk 16 · n 544 · Phase 3 · primary NCT03268005
  • -1.9% vs -0.7% wk 26 · n 105 · Phase 3 · primary NCT02911948
  • -1.5% vs -1.5% wk 26 · n 244 · Phase 3 · primary NCT02420262
  • -1.8% vs -1.1% wk 26 · n 278 · Phase 3 · primary NCT01952145
  • -1.3% vs -0.4% wk 26 · n 292 · Phase 3 · primary NCT01676116
  • -0.6% vs -0.5% wk 16 · n 143 · Phase 3 · primary NCT04588259
  • -0.1% vs -0.1% wk 16 · n 138 · Phase 3 · primary NCT01570751
  • -1.1% vs -1.1% twice daily · wk 4.14 · n 121 · Phase 3 · primary NCT02648217
  • -0.9% vs -0.8% wk 104 · n 2431 · Phase 3 · secondary NCT01959529
  • -0.9% vs -1.1% once daily · wk 104 · n 773 · Phase 3 · secondary NCT00982644
  • -0.5% vs -0.5% wk 88 · n 694 · Phase 3 · secondary NCT03078478
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • -2.0% vs -1.7% wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -0.5% vs 0% once weekly · wk 26 · n 40 · Phase 4 · primary NCT04538352
—Not reported
Body weight, change (kg)1.2 vs 3vs Insulin Glarginewk 104 · n 506NCT02501161
15 other results
  • 2.9 vs 1.7 wk 88 · n 701 · Phase 3 · secondary NCT03078478
  • 2.9 vs -1 wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • 4.1 vs -1 wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • 2.3 vs 2.8 wk 26 · n 294 · Phase 3 · secondary NCT04795531
  • 0.2 vs -2.5 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • 0.5 vs 2.2 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -1.4 vs 1.8 wk 26 · n 278 · Phase 3 · secondary NCT01952145
  • 1.2 vs 1.1 wk 16 · n 522 · Phase 3 · secondary NCT03268005
  • 1.3 vs -2.5 wk 26 · n 167 · Phase 3 · secondary NCT03172494
  • -0.7 vs 0.5 wk 26 · n 288 · Phase 3 · secondary NCT03175120
  • 2.8 vs 2.2 BID · wk 26 · n 359 · Phase 3 · secondary NCT02762578
  • -0.7 vs 0.7 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • -0.9 vs 2.6 wk 26 · n 244 · Phase 3 · secondary NCT02420262
  • 2 vs -0.8 wk 26 · n 292 · Phase 3 · secondary NCT01676116
  • -8.6 vs 1.4 once weekly · wk 26 · n 40 · Phase 4 · secondary NCT04538352
—Not reported
HbA1c below 7%75.3% vs 35.6%vs Liraglutide or Exenatidewk 26 · n 292NCT01676116—Not reported
Fasting plasma glucose, change-3.9 vs -3.7vs Insulin Glarginewk 104 · n 506NCT02501161
15 other results
  • -2.0 vs -1.4 wk 88 · n 685 · Phase 3 · secondary NCT03078478
  • -4.1 vs -2.6 wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -4.0 vs -2.6 wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • -3.0 vs -3.0 wk 26 · n 290 · Phase 3 · secondary NCT04795531
  • -3.6 vs -1.9 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • -4.0 vs -3.8 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -3.0 vs -0.6 wk 26 · n 285 · Phase 3 · secondary NCT01676116
  • 0.6 vs 0.7 wk 16 · n 533 · Phase 3 · secondary NCT03268005
  • -3.5 vs -1.9 wk 26 · n 167 · Phase 3 · secondary NCT03172494
  • -3.6 vs -2.8 wk 26 · n 289 · Phase 3 · secondary NCT03175120
  • -3.0 vs -1.6 BID · wk 26 · n 354 · Phase 3 · secondary NCT02762578
  • -2.8 vs -2.3 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • 0.4 vs 0.2 wk 16 · n 143 · Phase 3 · secondary NCT04588259
  • -0.8 vs 0 wk 16 · n 128 · Phase 3 · secondary NCT01570751
  • -2 vs -4.4 twice daily · wk 4.14 · n 115 · Phase 3 · secondary NCT02648217
—Not reported
3-point MACE (% with event)—Not posted · NCT05802862—Not reported

HbA1c, change

insulin degludec
-1.1% vs -1.2%vs IGlaronce daily · wk 52 · n 773NCT00982644
22 other results
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · primary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 271 · Phase 3 · primary NCT02607306
  • -1.4% vs -1.6% wk 26 · n 294 · Phase 3 · primary NCT04795531
  • -1.7% vs -1.2% wk 26 · n 341 · Phase 3 · primary NCT03172494
  • -1.2% vs -1.2% wk 26 · n 167 · Phase 3 · primary NCT03172494
  • -1.9% vs -1.1% wk 26 · n 289 · Phase 3 · primary NCT03175120
  • -1.5% vs -1.4% BID · wk 26 · n 359 · Phase 3 · primary NCT02762578
  • -0.1% vs -0.1% wk 16 · n 544 · Phase 3 · primary NCT03268005
  • -1.9% vs -0.7% wk 26 · n 105 · Phase 3 · primary NCT02911948
  • -1.5% vs -1.5% wk 26 · n 244 · Phase 3 · primary NCT02420262
  • -1.8% vs -1.1% wk 26 · n 278 · Phase 3 · primary NCT01952145
  • -1.3% vs -0.4% wk 26 · n 292 · Phase 3 · primary NCT01676116
  • -0.6% vs -0.5% wk 16 · n 143 · Phase 3 · primary NCT04588259
  • -0.1% vs -0.1% wk 16 · n 138 · Phase 3 · primary NCT01570751
  • -1.1% vs -1.1% twice daily · wk 4.14 · n 121 · Phase 3 · primary NCT02648217
  • -0.9% vs -0.8% wk 104 · n 2431 · Phase 3 · secondary NCT01959529
  • -0.9% vs -1.1% once daily · wk 104 · n 773 · Phase 3 · secondary NCT00982644
  • -0.5% vs -0.5% wk 88 · n 694 · Phase 3 · secondary NCT03078478
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • -2.0% vs -1.7% wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -0.5% vs 0% once weekly · wk 26 · n 40 · Phase 4 · primary NCT04538352
Insulin glargine (Toujeo)
—Not reported

Body weight, change (kg)

insulin degludec
1.2 vs 3vs Insulin Glarginewk 104 · n 506NCT02501161
15 other results
  • 2.9 vs 1.7 wk 88 · n 701 · Phase 3 · secondary NCT03078478
  • 2.9 vs -1 wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • 4.1 vs -1 wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • 2.3 vs 2.8 wk 26 · n 294 · Phase 3 · secondary NCT04795531
  • 0.2 vs -2.5 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • 0.5 vs 2.2 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -1.4 vs 1.8 wk 26 · n 278 · Phase 3 · secondary NCT01952145
  • 1.2 vs 1.1 wk 16 · n 522 · Phase 3 · secondary NCT03268005
  • 1.3 vs -2.5 wk 26 · n 167 · Phase 3 · secondary NCT03172494
  • -0.7 vs 0.5 wk 26 · n 288 · Phase 3 · secondary NCT03175120
  • 2.8 vs 2.2 BID · wk 26 · n 359 · Phase 3 · secondary NCT02762578
  • -0.7 vs 0.7 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • -0.9 vs 2.6 wk 26 · n 244 · Phase 3 · secondary NCT02420262
  • 2 vs -0.8 wk 26 · n 292 · Phase 3 · secondary NCT01676116
  • -8.6 vs 1.4 once weekly · wk 26 · n 40 · Phase 4 · secondary NCT04538352
Insulin glargine (Toujeo)
—Not reported

HbA1c below 7%

insulin degludec
75.3% vs 35.6%vs Liraglutide or Exenatidewk 26 · n 292NCT01676116
Insulin glargine (Toujeo)
—Not reported

Fasting plasma glucose, change

insulin degludec
-3.9 vs -3.7vs Insulin Glarginewk 104 · n 506NCT02501161
15 other results
  • -2.0 vs -1.4 wk 88 · n 685 · Phase 3 · secondary NCT03078478
  • -4.1 vs -2.6 wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -4.0 vs -2.6 wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • -3.0 vs -3.0 wk 26 · n 290 · Phase 3 · secondary NCT04795531
  • -3.6 vs -1.9 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • -4.0 vs -3.8 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -3.0 vs -0.6 wk 26 · n 285 · Phase 3 · secondary NCT01676116
  • 0.6 vs 0.7 wk 16 · n 533 · Phase 3 · secondary NCT03268005
  • -3.5 vs -1.9 wk 26 · n 167 · Phase 3 · secondary NCT03172494
  • -3.6 vs -2.8 wk 26 · n 289 · Phase 3 · secondary NCT03175120
  • -3.0 vs -1.6 BID · wk 26 · n 354 · Phase 3 · secondary NCT02762578
  • -2.8 vs -2.3 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • 0.4 vs 0.2 wk 16 · n 143 · Phase 3 · secondary NCT04588259
  • -0.8 vs 0 wk 16 · n 128 · Phase 3 · secondary NCT01570751
  • -2 vs -4.4 twice daily · wk 4.14 · n 115 · Phase 3 · secondary NCT02648217
Insulin glargine (Toujeo)
—Not reported

3-point MACE (% with event)

insulin degludec
—Not posted · NCT05802862
Insulin glargine (Toujeo)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. insulin degludec: 5 of 5 rows · Insulin glargine (Toujeo): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricinsulin degludecInsulin glargine (Toujeo)
HbA1c
absolute change · percentage points
No placebo or comparator arm
-2.02% (n=200) @ 32wka,b,c,d,e
NCT02298192 · Phase 3 · registry result, not featured evidence
show 1 more dose
-2.01% (n=189) @ 32wk
NCT02298192 · Phase 3 · registry result, not featured evidence
-1.29% (n=1651) @ 52wkb,c,d,e
NCT02451137 · Phase 4 · registry result, not featured evidence
Dropout rate
21.5%once dailyf
NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 25 more results
2%
NCT01959529 · Phase 3
0%once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
10.9%
NCT03336528 · Phase 4 · registry result, not featured evidence
—
NCT04588259 · Phase 3 · registry result, not featured evidence
2.7%
NCT04795531 · Phase 3 · registry result, not featured evidence
6.7%Insulin Degludec
NCT03172494 · Phase 3 · registry result, not featured evidence
5.5%Insulin Degludec/Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
4%
NCT03175120 · Phase 3 · registry result, not featured evidence
—
NCT03078478 · Phase 3 · registry result, not featured evidence
2.7%
NCT03268005 · Phase 3 · registry result, not featured evidence
4.3%
NCT02501161 · Phase 3 · registry result, not featured evidence
2.2%
NCT02906917 · Phase 3 · registry result, not featured evidence
8.5%Insulin Degludec
NCT02607306 · Phase 3 · registry result, not featured evidence
7.6%Insulin Degludec/Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
0%
NCT02911948 · Phase 3 · registry result, not featured evidence
4.8%
NCT02773368 · Phase 3 · registry result, not featured evidence
4.2%BID
NCT02762578 · Phase 3 · registry result, not featured evidence
0.8%
NCT02420262 · Phase 3 · registry result, not featured evidence
7.6%twice daily
NCT02648217 · Phase 3 · registry result, not featured evidence
2.9%IDegLira
NCT02298192 · Phase 3 · registry result, not featured evidence
9%IDegLira (1WT)
NCT02298192 · Phase 3 · registry result, not featured evidence
10.1%
NCT01952145 · Phase 3 · registry result, not featured evidence
5.5%Insulin Degludec/Liraglutide + Ora
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
—Insulin Degludec/Liraglutide +OADs
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
—
NCT01570751 · Phase 3 · registry result, not featured evidence
14.8%g
NCT03013985 · Phase 4 · registry result, not featured evidence
show 1 more result
14.9%
NCT02451137 · Phase 4 · registry result, not featured evidence
Discontinued due to AEs
2.6%once dailyf
NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 25 more results
0%
NCT01959529 · Phase 3
—once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
—
NCT03336528 · Phase 4 · registry result, not featured evidence
—
NCT04588259 · Phase 3 · registry result, not featured evidence
—
NCT04795531 · Phase 3 · registry result, not featured evidence
0.6%Insulin Degludec
NCT03172494 · Phase 3 · registry result, not featured evidence
1.4%Insulin Degludec/Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
0.7%
NCT03175120 · Phase 3 · registry result, not featured evidence
—
NCT03078478 · Phase 3 · registry result, not featured evidence
—
NCT03268005 · Phase 3 · registry result, not featured evidence
0.4%
NCT02501161 · Phase 3 · registry result, not featured evidence
0.4%
NCT02906917 · Phase 3 · registry result, not featured evidence
2.2%Insulin Degludec
NCT02607306 · Phase 3 · registry result, not featured evidence
2.9%Insulin Degludec/Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
—
NCT02911948 · Phase 3 · registry result, not featured evidence
—
NCT02773368 · Phase 3 · registry result, not featured evidence
0.3%BID
NCT02762578 · Phase 3 · registry result, not featured evidence
0.4%
NCT02420262 · Phase 3 · registry result, not featured evidence
0%twice daily
NCT02648217 · Phase 3 · registry result, not featured evidence
1%IDegLira
NCT02298192 · Phase 3 · registry result, not featured evidence
2.9%IDegLira (1WT)
NCT02298192 · Phase 3 · registry result, not featured evidence
3.2%
NCT01952145 · Phase 3 · registry result, not featured evidence
0.3%Insulin Degludec/Liraglutide + Ora
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
—Insulin Degludec/Liraglutide +OADs
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
—
NCT01570751 · Phase 3 · registry result, not featured evidence
—g
NCT03013985 · Phase 4 · registry result, not featured evidence
show 1 more result
2.6%
NCT02451137 · Phase 4 · registry result, not featured evidence
Serious AEs
15.1%once dailyf
NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 25 more results
38.6%
NCT01959529 · Phase 3
22.5%once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
3.7%
NCT03336528 · Phase 4 · registry result, not featured evidence
6.7%
NCT04588259 · Phase 3 · registry result, not featured evidence
5.1%
NCT04795531 · Phase 3 · registry result, not featured evidence
4%Insulin Degludec
NCT03172494 · Phase 3 · registry result, not featured evidence
3.9%Insulin Degludec/Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
4.3%
NCT03175120 · Phase 3 · registry result, not featured evidence
20.8%
NCT03078478 · Phase 3 · registry result, not featured evidence
7%
NCT03268005 · Phase 3 · registry result, not featured evidence
11.9%
NCT02501161 · Phase 3 · registry result, not featured evidence
6.8%
NCT02906917 · Phase 3 · registry result, not featured evidence
4.8%Insulin Degludec
NCT02607306 · Phase 3 · registry result, not featured evidence
6.2%Insulin Degludec/Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
2.9%
NCT02911948 · Phase 3 · registry result, not featured evidence
2.9%
NCT02773368 · Phase 3 · registry result, not featured evidence
4.4%BID
NCT02762578 · Phase 3 · registry result, not featured evidence
4.8%
NCT02420262 · Phase 3 · registry result, not featured evidence
3.8%twice daily
NCT02648217 · Phase 3 · registry result, not featured evidence
6.7%IDegLira
NCT02298192 · Phase 3 · registry result, not featured evidence
3.3%IDegLira (1WT)
NCT02298192 · Phase 3 · registry result, not featured evidence
1.8%
NCT01952145 · Phase 3 · registry result, not featured evidence
—Insulin Degludec/Liraglutide + Ora
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
3.1%Insulin Degludec/Liraglutide +OADs
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
2.9%
NCT01570751 · Phase 3 · registry result, not featured evidence
19.4%g
NCT03013985 · Phase 4 · registry result, not featured evidence
show 1 more result
9.8%
NCT02451137 · Phase 4 · registry result, not featured evidence
Most frequent reported AEs
once dailyf
nasopharyngitis 23.9%
headache 13.8%
diarrhoea 10.8%
NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 23 more results
once weekly
pain 17.5%
upper respiratory infection 0%
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
emergency room visit for bilateral knee pain 1.2%
emergency room visit for congestive heart failure 1.2%
emergency room visit for wound infection 1.2%
NCT03336528 · Phase 4 · registry result, not featured evidence
diabetic retinopathy 14.7%
hyperlipidaemia 14%
upper respiratory tract infection 9.3%
NCT04588259 · Phase 3 · registry result, not featured evidence
covid-19 4.8%
influenza 3.1%
diabetic retinopathy 2%
NCT04795531 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 17.7%
nasopharyngitis 5.1%
diabetic retinopathy 3.4%
NCT03172494 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 18.4%
diabetic retinopathy 7.8%
lipase increased 7.5%
NCT03172494 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 12.6%
lipase increased 12%
diabetic retinopathy 11.6%
NCT03175120 · Phase 3 · registry result, not featured evidence
nasopharyngitis 19%
upper respiratory tract infection 18.1%
diarrhoea 9%
NCT03078478 · Phase 3 · registry result, not featured evidence
nasopharyngitis 5.9%
NCT03268005 · Phase 3 · registry result, not featured evidence
headache 11.5%
nasopharyngitis 11.3%
diarrhoea 7.7%
NCT02501161 · Phase 3 · registry result, not featured evidence
nasopharyngitis 13.6%
headache 10.2%
back pain 6%
NCT02906917 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 33.6%
weight increased 7%
pharyngitis 5.5%
NCT02607306 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 38.5%
constipation 9.8%
diabetic retinopathy 6.2%
NCT02607306 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 20%
diabetic retinopathy 16.2%
diarrhoea 14.3%
NCT02911948 · Phase 3 · registry result, not featured evidence
headache 8.6%
viral upper respiratory tract infection 7.7%
lipase increased 5.7%
NCT02773368 · Phase 3 · registry result, not featured evidence
BID
upper respiratory tract infection 21.1%
diabetic retinopathy 10%
viral upper respiratory tract infection 2.5%
NCT02762578 · Phase 3 · registry result, not featured evidence
nausea 11.1%
influenza 7.1%
diarrhoea 6.3%
NCT02420262 · Phase 3 · registry result, not featured evidence
twice daily
blood glucose decreased 35.4%
upper respiratory tract infection 6.2%
pyrexia 3.1%
NCT02648217 · Phase 3 · registry result, not featured evidence
nausea 5.2%
nasopharyngitis 4.3%
NCT02298192 · Phase 3 · registry result, not featured evidence
nasopharyngitis 6.2%
nausea 5.3%
NCT02298192 · Phase 3 · registry result, not featured evidence
nausea 9.4%
diarrhoea 7.2%
vomiting 5%
NCT01952145 · Phase 3 · registry result, not featured evidence
lipase increased 10%
headache 9.3%
nasopharyngitis 8.9%
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 1.4%
NCT01570751 · Phase 3 · registry result, not featured evidence
g
trauma 3.7%
cough 0.9%
gastroparesis 0.9%
NCT03013985 · Phase 4 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 3 versus Phase 4.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. eAssessment timepoints differ: 32 weeks versus 52 weeks.
  6. fPopulation comparability has not been reviewed for 25 of these studies.
  7. gPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

insulin degludec

HbA1c -1.06% (n=773) vs -1.19% (n=257) IGlar @ 52wkonce daily
absolute change · percentage points
NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 22 more results
-0.95% (n=773) vs -1.11% (n=257) IGlar @ 104wkonce daily
NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.86% (n=2431) vs -0.84% (n=2404) Insulin Glargine @ 104wk
NCT01959529 · Phase 3
-0.5% (n=40) vs 0% (n=20) Insulin @ 26wkonce weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
-0.57% (n=143) vs -0.54% (n=145) NovoRapid @ 16wk
NCT04588259 · Phase 3 · registry result, not featured evidence
-1.36% (n=294) vs -1.57% (n=294) Insulin Icodec @ 26wk
NCT04795531 · Phase 3 · registry result, not featured evidence
-1.71% (n=341) vs -1.16% (n=151) Liraglutide @ 26wk
NCT03172494 · Phase 3 · registry result, not featured evidence
-1.2% (n=167) vs -1.16% (n=151) Liraglutide @ 26wk
NCT03172494 · Phase 3 · registry result, not featured evidence
-1.93% (n=289) vs -1.06% (n=138) Insulin Degludec @ 26wk
NCT03175120 · Phase 3 · registry result, not featured evidence
-0.54% (n=694) vs -0.46% (n=700) Insulin Glargine @ 88wk
NCT03078478 · Phase 3 · registry result, not featured evidence
-0.15% (n=544) vs -0.09% (n=539) NovoRapid @ 16wk
NCT03268005 · Phase 3 · registry result, not featured evidence
-1.99% (n=506) vs -1.69% (n=506) Insulin Glargine @ 26wk
NCT02501161 · Phase 3 · registry result, not featured evidence
-2.42% (n=275) vs -1.8% (n=273) Liraglutide @ 52wk
NCT02607306 · Phase 3 · registry result, not featured evidence
-1.8% (n=271) vs -1.8% (n=273) Liraglutide @ 52wk
NCT02607306 · Phase 3 · registry result, not featured evidence
-2.42% (n=275) vs -1.8% (n=273) Liraglutide @ 52wk
NCT02607306 · Phase 3 · registry result, not featured evidence
-1.8% (n=271) vs -1.8% (n=273) Liraglutide @ 52wk
NCT02607306 · Phase 3 · registry result, not featured evidence
-1.95% (n=105) vs -0.65% (n=105) Insulin Degludec @ 26wk
NCT02911948 · Phase 3 · registry result, not featured evidence
-1.48% (n=359) vs -1.4% (n=182) BIAsp 30 @ 26wkBID
NCT02762578 · Phase 3 · registry result, not featured evidence
-1.48% (n=244) vs -1.46% (n=245) IGlar + IAsp @ 26wk
NCT02420262 · Phase 3 · registry result, not featured evidence
-1.11% (n=121) vs -1.13% (n=124) Biphasic Insulin Aspart 30 @ 4.14wktwice daily
NCT02648217 · Phase 3 · registry result, not featured evidence
-1.81% (n=278) vs -1.13% (n=279) Insulin Glargine (IGlar) @ 26wk
NCT01952145 · Phase 3 · registry result, not featured evidence
-1.32% (n=292) vs -0.37% (n=146) Liraglutide or Exenatide @ 26wk
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
-0.1% (n=138) vs -0.1% (n=138) IGlar @ 16wk
NCT01570751 · Phase 3 · registry result, not featured evidence
Time to First MACE 8.5% (n=3818) vs 9.3% (n=3819) Insulin Glargine
event count · % of participants
First EAC-confirmed MACE
NCT01959529 · Phase 3 · converted to % from 325 Participants as posted
Non-fatal MI 3.7% (n=3818) vs 4.3% (n=3819) Insulin Glargine
event count · % of participants
Myocardial infarction (non-fatal)
NCT01959529 · Phase 3 · converted to % from 143 Participants as posted
Stroke 1.8% (n=3818) vs 1.9% (n=3819) Insulin Glargine
responder rate · % of participants
Stroke (non-fatal)
NCT01959529 · Phase 3 · converted to % from 68 Participants as posted
CV Death 3% (n=3818) vs 3.1% (n=3819) Insulin Glargine
responder rate · % of participants
Cardiovascular death
NCT01959529 · Phase 3 · converted to % from 114 Participants as posted
Hypoglycemia Episodes Level 3 280 vs 472 Insulin Glargine count
event count · count
NCT01959529 · Phase 3
show 2 more results
2 vs 0 Insulin Icodec count @ 31wk
NCT04795531 · Phase 3 · registry result, not featured evidence
0 vs 0 Insulin Icodec count @ 26wk
NCT04795531 · Phase 3 · registry result, not featured evidence
Hypoglycemia Event Incidence 4.9% (n=3818) vs 6.6% (n=3819) Insulin Glargine
event rate · % of participants
NCT01959529 · Phase 3 · converted to % from 187 Participants as posted
Weight -8.6 vs 1.4 Insulin kg @ 26wkonce weekly
absolute change · kg
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
show 15 more results
2.32 vs 2.77 Insulin Icodec kg @ 26wk
NCT04795531 · Phase 3 · registry result, not featured evidence
0.2 vs -2.5 Liraglutide kg @ 26wk
NCT03172494 · Phase 3 · registry result, not featured evidence
1.3 vs -2.5 Liraglutide kg @ 26wk
NCT03172494 · Phase 3 · registry result, not featured evidence
-0.7 vs 0.5 Insulin Degludec kg @ 26wk
NCT03175120 · Phase 3 · registry result, not featured evidence
2.9 vs 1.7 Insulin Glargine kg @ 88wk
NCT03078478 · Phase 3 · registry result, not featured evidence
1.19 vs 1.12 NovoRapid kg @ 16wk
NCT03268005 · Phase 3 · registry result, not featured evidence
0.5 vs 2.2 Insulin Glargine kg @ 26wk
NCT02501161 · Phase 3 · registry result, not featured evidence
1.2 vs 3 Insulin Glargine kg @ 104wk
NCT02501161 · Phase 3 · registry result, not featured evidence
2.9 vs -1 Liraglutide kg @ 52wk
NCT02607306 · Phase 3 · registry result, not featured evidence
4.1 vs -1 Liraglutide kg @ 52wk
NCT02607306 · Phase 3 · registry result, not featured evidence
-0.7 vs 0.7 Insulin Degludec kg @ 26wk
NCT02911948 · Phase 3 · registry result, not featured evidence
2.82 vs 2.21 BIAsp 30 kg @ 26wkBID
NCT02762578 · Phase 3 · registry result, not featured evidence
-0.93 vs 2.64 IGlar + IAsp kg @ 26wk
NCT02420262 · Phase 3 · registry result, not featured evidence
-1.4 vs 1.8 Insulin Glargine (IGlar) kg @ 26wk
NCT01952145 · Phase 3 · registry result, not featured evidence
2 vs -0.8 Liraglutide or Exenatide kg @ 26wk
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
HbA1c -0.5 vs 0 Insulin actual mean A1C change @ 26wkonce weekly
absolute change · actual mean A1C change
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
Daily Glucose mg/dL 9.98 vs 10.03 Glargine mmol/L @ 1wk
absolute value · mmol/L
Day 1 up to Day 10
NCT03336528 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 179.75 mg/dL as posted
Daily Glucose mg/dL 8.71 vs 7.94 Glargine mmol/L @ 4wk
absolute value · mmol/L
Day after discharge up to the 4 week post-discharge study visit
NCT03336528 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 157 mg/dL as posted
Daily Glucose mg/dL 8.25 vs 7.43 Glargine mmol/L @ 12wk
absolute value · mmol/L
4 week post-discharge up to the 12 week post-discharge study visit
NCT03336528 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 148.7 mg/dL as posted

+ 110 further endpoints in the CSV export.

Insulin glargine (Toujeo)

Daily Glucose mg/dL 10.32 vs 10.21 Glargine U100 mmol/L
absolute value · mmol/L
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 186 mg/dL as posted
show 6 more results
9.52 vs 9.13 Glargine U100 mmol/L @ 12wk*
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 171.6 mg/dL as posted
8.33 vs 7.46 Glargine U100 mmol/L @ 12wk*
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 150 mg/dL as posted
8.45 vs 8.64 Glargine U100 mmol/L @ 12wk*
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 152.3 mg/dL as posted
9.42 vs 10.92 Glargine U100 mmol/L*
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 169.71 mg/dL as posted
10.74 vs 10.75 Glargine U100 mmol/L*
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 193.53 mg/dL as posted
10.46 vs 9.69 Glargine U100 mmol/L*
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 188.46 mg/dL as posted
Time in Range 50.3% (n=92) vs 54.9% (n=84) Glargine U100 @ 12wk
absolute value · percentage points
NCT03013985 · Phase 4 · registry result, not featured evidence
Hypoglycemia Event Incidence 8.7% (n=92) vs 9.5% (n=84) Glargine U100 @ 12wk
responder rate · % of participants
NCT03013985 · Phase 4 · registry result, not featured evidence
Severe Hypoglycemia Event Incidence 0% (n=92) vs 6% (n=84) Glargine U100 @ 12wk
responder rate · % of participants
NCT03013985 · Phase 4 · registry result, not featured evidence
HbA1c Target Attainment Without Hypoglycemia 31.3% (n=1651) @ 26wk
responder rate · % of participants
No placebo or comparator arm
NCT02451137 · Phase 4 · registry result, not featured evidence
show 1 more result
37.3% (n=1651) @ 26wk
NCT02451137 · Phase 4 · registry result, not featured evidence
Fasting Plasma Glucose -2.71 mmol/L @ 26wk
absolute change · mmol/L
No placebo or comparator arm
NCT02451137 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -48.9 mg/dL as posted
show 1 more result
-2.66 mmol/L @ 52wk*
NCT02451137 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -48 mg/dL as posted
Weight 1.02 kg @ 26wk
absolute change · kg
No placebo or comparator arm
NCT02451137 · Phase 4 · registry result, not featured evidence
show 1 more result
1.51 kg @ 52wk
NCT02451137 · Phase 4 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin degludec's landscape · Insulin glargine (Toujeo)'s landscape